劳拉替尼用于ALK阳性非小细胞肺癌：重塑治疗格局的最终生存数据。 - Suppr

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape.

作者信息

Katayama Yuki

机构信息

Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

出版信息

Transl Lung Cancer Res. 2025 Jul 31;14(7):2364-2368. doi: 10.21037/tlcr-2025-466. Epub 2025 Jul 16.

DOI:10.21037/tlcr-2025-466

PMID:40799415

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337068/

Abstract

摘要

相似文献

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape.劳拉替尼用于ALK阳性非小细胞肺癌：重塑治疗格局的最终生存数据。

Transl Lung Cancer Res. 2025 Jul 31;14(7):2364-2368. doi: 10.21037/tlcr-2025-466. Epub 2025 Jul 16.

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.洛拉替尼在瑞典一线治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌成人患者中的成本效益分析。

Appl Health Econ Health Policy. 2023 Jul;21(4):661-672. doi: 10.1007/s40258-023-00807-7. Epub 2023 May 12.

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.洛拉替尼用于治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌：IFCT-1803 LORLATU队列研究结果

Eur J Cancer. 2022 May;166:51-59. doi: 10.1016/j.ejca.2022.01.018. Epub 2022 Mar 9.

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）作为一线治疗ALK 阳性晚期非小细胞肺癌（NSCLC）的比较：系统评价和网络荟萃分析。

Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.

Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.抗表皮生长因子受体（EGFR）疗法可克服因EGFR激活介导的对第三代间变性淋巴瘤激酶（ALK）-酪氨酸激酶抑制剂劳拉替尼的获得性耐药。

Acta Pharmacol Sin. 2025 Mar 21. doi: 10.1038/s41401-025-01511-z.

Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。

Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.

Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。

Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.关键2期研究中劳拉替尼治疗ALK阳性非小细胞肺癌患者的最终总生存期和长期安全性：简要报告

J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.动态监测循环肿瘤 DNA 分析 ALK 阳性经治 NSCLC 患者中 lorlatinib 的遗传特征和耐药谱。

Thorac Cancer. 2023 Jul;14(20):1980-1990. doi: 10.1111/1759-7714.14980. Epub 2023 Jun 2.

本文引用的文献

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain.劳拉替尼在西班牙同情用药项目中治疗的ALK和ROS1重排转移性非小细胞肺癌患者中的疗效和安全性。

Cancer Treat Res Commun. 2025;43:100905. doi: 10.1016/j.ctarc.2025.100905. Epub 2025 Mar 22.

AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.巨噬细胞和MMP11阳性成纤维细胞产生的GAS6增强了AXL介导的ALK重排非小细胞肺癌的耐药性。

Cancer Sci. 2025 Apr;116(4):1034-1047. doi: 10.1111/cas.70006. Epub 2025 Feb 4.

J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings.劳拉替尼用于ALK阳性肺癌二线及以上治疗：资源受限环境下的真实世界数据

BJC Rep. 2024 May 1;2(1):35. doi: 10.1038/s44276-024-00055-9.

Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.简明摘要：洛拉替尼与克唑替尼治疗非小细胞肺癌的CROWN研究5年结果

Future Oncol. 2024 Dec;20(40):3377-3387. doi: 10.1080/14796694.2024.2406117. Epub 2024 Oct 3.

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.NVL-655是一种对多种ALK突变癌蛋白具有选择性且能穿透血脑屏障的抑制剂，包括对劳拉替尼耐药的复合突变。

Cancer Discov. 2024 Dec 2;14(12):2367-2386. doi: 10.1158/2159-8290.CD-24-0231.

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.真实世界中第二代和第三代 ALK 酪氨酸激酶抑制剂治疗顺序和疗效在 ALK 阳性晚期非小细胞肺癌中的应用。

Lung Cancer. 2024 Sep;195:107919. doi: 10.1016/j.lungcan.2024.107919. Epub 2024 Aug 3.

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.洛拉替尼治疗 ALK+晚期非小细胞肺癌不良事件管理的专家共识。

Clin Drug Investig. 2024 Aug;44(8):553-576. doi: 10.1007/s40261-024-01379-7. Epub 2024 Jul 31.

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies.癌症中的ALK抑制剂：耐药机制与治疗管理策略

Cancer Drug Resist. 2024 May 23;7:20. doi: 10.20517/cdr.2024.25. eCollection 2024.

Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。

J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献